A Phase 1, Randomized, Open-Label, Single-Dose, 4-Way Crossover Study to Assess the Relative Bioavailability of Four 80 mg Febuxostat XR Formulations
收藏DataCite Commons2025-12-03 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00003347/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This study will assess the relative bioavailability, safety and tolerability following administration of 80 mg single oral doses of 4 febuxostat extended release (XR) formulations.
提供机构：
Vivli
创建时间：
2019-03-06
